November 04, 2024
Developing treatments for people with mental health conditions
October 14, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare
September 27, 2024
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
March 11, 2024
New partnership to develop schizophrenia treatments
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
January 09, 2024
Kicking off 2024 with five new R&D partnerships
January 09, 2024
New study paves the way for liver cirrhosis treatments
January 03, 2024
Partnership for new liver disease treatments with Ribo
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
May 09, 2023
IL-11 inhibitor antibody clinical development launched
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
December 19, 2022
New digital Tx collab with Click
October 20, 2022
AI and Data Science Fellowship with University of Tuebingen
July 06, 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
June 14, 2022
Option to Acquire Trutino Biosciences
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
March 29, 2022
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
March 01, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
October 27, 2021
Mental health collaboration with King’s College London
October 26, 2021
Partnership to Develop Urea Cycle Disorders Therapy
October 19, 2021
Cystic Fibrosis Gene Therapy Takes to Next step
October 06, 2021
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
September 21, 2021
Acquisition to advance cancer immunology research
September 16, 2021
Clinical collaboration with Amgen on KRAS
May 10, 2021
Biomedical Data Science Fellowship Program with Yale
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
March 16, 2021
Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors
March 01, 2021
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
January 12, 2021
Collaboration with Enara Bio on Cancer Immunotherapies
January 12, 2021
Boehringer Ingelheim partners with PetMedix
December 10, 2020
Boehringer Ingelheim to acquire NBE-Therapeutics
December 09, 2020
Boehringer Ingelheim to acquire Labor Dr. Merk and Kollegen
December 07, 2020
Collaboration with Proxygen on Molecular Glue Degraders
October 27, 2020
Partnership leads to innovative needle free injection device for pigs
October 14, 2020
Expanded alliance with OBT advances cancer immunology pipeline
September 30, 2020
Boehringer Ingelheim and Fraunhofer IME launch collaboration
September 29, 2020
Boehringer Ingelheim invests in partnership to further develop the pet market in China
September 17, 2020
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
September 11, 2020
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
September 07, 2020
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic Retinopathy
July 27, 2020
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health
December 30, 2019
Milestone for Biopharmaceuticals in China
April 03, 2019
Positivity… just a paw away
April 02, 2019
Boehringer Ingelheim launches BVDzero scholarship for veterinary students
February 26, 2019
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development
December 17, 2018
Boehringer Ingelheim launches a tool to aid in the prevention of African swine fever
December 11, 2018
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
December 04, 2018
Boehringer Ingelheim launches "LastMile" initiative in Sub-Saharan Africa
November 22, 2018
Boehringer Ingelheim partners with Ipsos to gain insights on human-animal bond in Europe
August 06, 2018
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
May 15, 2018
Boehringer Ingelheim inaugurates its new integrated Asian Veterinary Research & Development Center
April 11, 2018
Boehringer Ingelheim to invest 65 million euros in avian vaccines in France
March 28, 2018
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Senior Media Relations Manager
E-Mail:
mark_william.valentiner@boehringer-ingelheim.com
Tel.: +49 (6132) 77-170136
Media Relations Manager
E-Mail:
valerie-chiara.nestle@boehringer-ingelheim.com
Phone Number:
+49 (7351) 54-175075
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799
Head of Innovation Unit Communications
E-Mail: camilla.krogh_lauritzen@boehringer-ingelheim.com
Phone Number: +45 2272 4806